Ocular Inflammation Treatment Market is Projected to Reach Valuation of US$ 530 Million by 2026

Ocular Inflammation Treatment Market Segmentation by Treatment Type -
Corticosteroids, Antibiotics, Monoclonal Antibodies, Immunosuppressant,
Cycloplegic Agents, Antivirals; Disease Type - Anterior Uveitis, Posterior
Uveitis, Panuveitis, Intermediate Uveitis; Mode of Administration -
Topical, Injectables, Oral, and Others; Distribution Channel - Hospital
Pharmacies, Retail Pharmacies, Online Pharmacies, and Drug Stores, and
Forecast 2017-2026
©2019 Transparency Market Research, All Rights Reserved

Sr. No.
Chapter 1
Chapter 2
Chapter 3
Chapter 4
Chapter 5
Chapter 6
Chapter 7
Chapter 8
Chapter 9
Chapter 10
Chapter 11
Chapter 12
Chapter 13
Chapter 14
Content
Preface
Assumptions and Research Methodology
Market Overview
Market Dynamics
Global Ocular Inflammation Treatment Market Analysis and Forecasts, By Software Type
Global Ocular Inflammation Treatment Market Analysis, by Modality
Global Ocular Inflammation Treatment Market Analysis, by Application
Global Ocular Inflammation Treatment Market Analysis, by End-user
Global Ocular Inflammation Treatment Market Analysis and Forecast by Region
Europe Ocular Inflammation Treatment Market Analysis and Forecast
Asia Pacific Ocular Inflammation Treatment Market Analysis and Forecast
Latin America Ocular Inflammation Treatment Market Analysis and Forecast
Middle East & Africa Ocular Inflammation Treatment Market Analysis and Forecast
Competition Landscape
©2019 Transparency Market Research, All Rights Reserved

Eye inflammations or uveitis are becoming a common problem for people across
global geographies.
New drugs are being discovered to treat ocular inflammations, and companies are
investing millions for their approval through regulatory pipelines.
Patients are exhibiting a particular preference to the type of ocular inflammation
treatment being adopted, considering the range of treatment options, their
comparative effectiveness, and convenience in terms of mode of administration.
The global market for ocular inflammation treatment is expected to grow sharply in
the coming years.
©2019 Transparency Market Research, All Rights Reserved

Key projections from the study assess the global ocular inflammation treatment
market to touch a US$ 1 billion value by the end of 2026.
Increasing contamination of environment by emission of toxins has elevated the
risks of ocular inflammation, also known as uveitis.
Evolving medical technologies and drug discovery developments have paved way
for effective treatment of ocular inflammation.
Prominent market players are diversifying their product lines to cater treatment of
all forms of uveitis occurring worldwide.
©2019 Transparency Market Research, All Rights Reserved

Regulatory stance of the FDA towards clearing uveitis drugs from the pipelines is
improving, and market players are being favored to introduce novel administration
techniques for ocular inflammation treatments.
During the period of assessment, 2017-2026, the global market for ocular
inflammation treatments is pegged to expand at a CAGR of 6.9% in terms of value.
In addition to Allergan, TMR also observes high stakes of Novartis AG, Valeant
Pharmaceuticals International, Inc., Abbvie, Inc., Alimera Sciences, Inc., Eyegate
Pharmaceuticals, Inc., pSivida Corp., Pfizer, Inc., Cipla Ltd., and Akorn, Inc. in the
global ocular inflammation treatment market over the coming years.
©2019 Transparency Market Research, All Rights Reserved

To know more about us, please visit our website
www.transparencymarketresearch.com
For sales queries or new topics email us on:
sales@transparencymarketresearch.com
Thank You
©2019 Transparency Market Research, All Rights Reserved